Cargando…
Novel Prognostic Signatures of Hepatocellular Carcinoma Based on Metabolic Pathway Phenotypes
Hepatocellular carcinoma is a disastrous cancer with an aberrant metabolism. In this study, we aimed to assess the role of metabolism in the prognosis of hepatocellular carcinoma. Ten metabolism-related pathways were identified to classify the hepatocellular carcinoma into two clusters: Metabolism_H...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168273/ https://www.ncbi.nlm.nih.gov/pubmed/35677150 http://dx.doi.org/10.3389/fonc.2022.863266 |
_version_ | 1784720968295383040 |
---|---|
author | Ye, Tingbo Lin, Leilei Cao, Lulu Huang, Weiguo Wei, Shengzhe Shan, Yunfeng Zhang, Zhongjing |
author_facet | Ye, Tingbo Lin, Leilei Cao, Lulu Huang, Weiguo Wei, Shengzhe Shan, Yunfeng Zhang, Zhongjing |
author_sort | Ye, Tingbo |
collection | PubMed |
description | Hepatocellular carcinoma is a disastrous cancer with an aberrant metabolism. In this study, we aimed to assess the role of metabolism in the prognosis of hepatocellular carcinoma. Ten metabolism-related pathways were identified to classify the hepatocellular carcinoma into two clusters: Metabolism_H and Metabolism_L. Compared with Metabolism_L, patients in Metabolism_H had lower survival rates with more mutated TP53 genes and more immune infiltration. Moreover, risk scores for predicting overall survival based on eleven differentially expressed metabolic genes were developed by the least absolute shrinkage and selection operator (LASSO)-Cox regression model in The Cancer Genome Atlas (TCGA) dataset, which was validated in the International Cancer Genome Consortium (ICGC) dataset. The immunohistochemistry staining of liver cancer patient specimens also identified that the 11 genes were associated with the prognosis of liver cancer patients. Multivariate Cox regression analyses indicated that the differentially expressed metabolic gene-based risk score was also an independent prognostic factor for overall survival. Furthermore, the risk score (AUC = 0.767) outperformed other clinical variables in predicting overall survival. Therefore, the metabolism-related survival-predictor model may predict overall survival excellently for HCC patients. |
format | Online Article Text |
id | pubmed-9168273 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91682732022-06-07 Novel Prognostic Signatures of Hepatocellular Carcinoma Based on Metabolic Pathway Phenotypes Ye, Tingbo Lin, Leilei Cao, Lulu Huang, Weiguo Wei, Shengzhe Shan, Yunfeng Zhang, Zhongjing Front Oncol Oncology Hepatocellular carcinoma is a disastrous cancer with an aberrant metabolism. In this study, we aimed to assess the role of metabolism in the prognosis of hepatocellular carcinoma. Ten metabolism-related pathways were identified to classify the hepatocellular carcinoma into two clusters: Metabolism_H and Metabolism_L. Compared with Metabolism_L, patients in Metabolism_H had lower survival rates with more mutated TP53 genes and more immune infiltration. Moreover, risk scores for predicting overall survival based on eleven differentially expressed metabolic genes were developed by the least absolute shrinkage and selection operator (LASSO)-Cox regression model in The Cancer Genome Atlas (TCGA) dataset, which was validated in the International Cancer Genome Consortium (ICGC) dataset. The immunohistochemistry staining of liver cancer patient specimens also identified that the 11 genes were associated with the prognosis of liver cancer patients. Multivariate Cox regression analyses indicated that the differentially expressed metabolic gene-based risk score was also an independent prognostic factor for overall survival. Furthermore, the risk score (AUC = 0.767) outperformed other clinical variables in predicting overall survival. Therefore, the metabolism-related survival-predictor model may predict overall survival excellently for HCC patients. Frontiers Media S.A. 2022-05-23 /pmc/articles/PMC9168273/ /pubmed/35677150 http://dx.doi.org/10.3389/fonc.2022.863266 Text en Copyright © 2022 Ye, Lin, Cao, Huang, Wei, Shan and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Ye, Tingbo Lin, Leilei Cao, Lulu Huang, Weiguo Wei, Shengzhe Shan, Yunfeng Zhang, Zhongjing Novel Prognostic Signatures of Hepatocellular Carcinoma Based on Metabolic Pathway Phenotypes |
title | Novel Prognostic Signatures of Hepatocellular Carcinoma Based on Metabolic Pathway Phenotypes |
title_full | Novel Prognostic Signatures of Hepatocellular Carcinoma Based on Metabolic Pathway Phenotypes |
title_fullStr | Novel Prognostic Signatures of Hepatocellular Carcinoma Based on Metabolic Pathway Phenotypes |
title_full_unstemmed | Novel Prognostic Signatures of Hepatocellular Carcinoma Based on Metabolic Pathway Phenotypes |
title_short | Novel Prognostic Signatures of Hepatocellular Carcinoma Based on Metabolic Pathway Phenotypes |
title_sort | novel prognostic signatures of hepatocellular carcinoma based on metabolic pathway phenotypes |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168273/ https://www.ncbi.nlm.nih.gov/pubmed/35677150 http://dx.doi.org/10.3389/fonc.2022.863266 |
work_keys_str_mv | AT yetingbo novelprognosticsignaturesofhepatocellularcarcinomabasedonmetabolicpathwayphenotypes AT linleilei novelprognosticsignaturesofhepatocellularcarcinomabasedonmetabolicpathwayphenotypes AT caolulu novelprognosticsignaturesofhepatocellularcarcinomabasedonmetabolicpathwayphenotypes AT huangweiguo novelprognosticsignaturesofhepatocellularcarcinomabasedonmetabolicpathwayphenotypes AT weishengzhe novelprognosticsignaturesofhepatocellularcarcinomabasedonmetabolicpathwayphenotypes AT shanyunfeng novelprognosticsignaturesofhepatocellularcarcinomabasedonmetabolicpathwayphenotypes AT zhangzhongjing novelprognosticsignaturesofhepatocellularcarcinomabasedonmetabolicpathwayphenotypes |